Considering HER2 heterogeneity as a prognostic marker, HER2 amplification has also been identified as a key mechanism driving resistance to anti-EGFR therapies in CRC by sustaining downstream signaling [28]. The gene discussed is ERBB2; the disease is colorectal carcinoma.